OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
APOE ε4: The most prevalent yet understudied risk factor for Alzheimer's disease
Daniel M. Michaelson
Alzheimer s & Dementia (2014) Vol. 10, Iss. 6, pp. 861-868
Closed Access | Times Cited: 296
Daniel M. Michaelson
Alzheimer s & Dementia (2014) Vol. 10, Iss. 6, pp. 861-868
Closed Access | Times Cited: 296
Showing 1-25 of 296 citing articles:
2019 Alzheimer's disease facts and figures
Alzheimer s & Dementia (2019) Vol. 15, Iss. 3, pp. 321-387
Closed Access | Times Cited: 2176
Alzheimer s & Dementia (2019) Vol. 15, Iss. 3, pp. 321-387
Closed Access | Times Cited: 2176
2020 Alzheimer's disease facts and figures
In this phase, individuals have measurable brain changes that indicate the earliest signs of Alzheimer's disease, but they have not yet developed symptoms such as memory loss. Examples of measurable brain changes …, et al.
Alzheimer s & Dementia (2020) Vol. 16, Iss. 3, pp. 391-460
Open Access | Times Cited: 2150
In this phase, individuals have measurable brain changes that indicate the earliest signs of Alzheimer's disease, but they have not yet developed symptoms such as memory loss. Examples of measurable brain changes …, et al.
Alzheimer s & Dementia (2020) Vol. 16, Iss. 3, pp. 391-460
Open Access | Times Cited: 2150
2023 Alzheimer's disease facts and figures
Alzheimer s & Dementia (2023) Vol. 19, Iss. 4, pp. 1598-1695
Open Access | Times Cited: 2044
Alzheimer s & Dementia (2023) Vol. 19, Iss. 4, pp. 1598-1695
Open Access | Times Cited: 2044
2022 Alzheimer's disease facts and figures
Alzheimer s & Dementia (2022) Vol. 18, Iss. 4, pp. 700-789
Closed Access | Times Cited: 1997
Alzheimer s & Dementia (2022) Vol. 18, Iss. 4, pp. 700-789
Closed Access | Times Cited: 1997
In the past, was often used to describe the dementia phase of the disease. Today we know that dementia is only …, Adult Disease, et al.
Alzheimer s & Dementia (2021) Vol. 17, Iss. 3, pp. 327-406
Closed Access | Times Cited: 1928
Plasma β-amyloid in Alzheimer’s disease and vascular disease
Shorena Janelidze, Erik Stomrud, Sebastian Palmqvist, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 513
Shorena Janelidze, Erik Stomrud, Sebastian Palmqvist, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 513
The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features
Rik Ossenkoppele, Yolande A.L. Pijnenburg, David C. Perry, et al.
Brain (2015) Vol. 138, Iss. 9, pp. 2732-2749
Open Access | Times Cited: 467
Rik Ossenkoppele, Yolande A.L. Pijnenburg, David C. Perry, et al.
Brain (2015) Vol. 138, Iss. 9, pp. 2732-2749
Open Access | Times Cited: 467
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward
Michaël E. Belloy, Valerio Napolioni, Michael D. Greicius
Neuron (2019) Vol. 101, Iss. 5, pp. 820-838
Open Access | Times Cited: 441
Michaël E. Belloy, Valerio Napolioni, Michael D. Greicius
Neuron (2019) Vol. 101, Iss. 5, pp. 820-838
Open Access | Times Cited: 441
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Mirna Safieh, Amos D. Korczyn, Daniel M. Michaelson
BMC Medicine (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 384
Mirna Safieh, Amos D. Korczyn, Daniel M. Michaelson
BMC Medicine (2019) Vol. 17, Iss. 1
Open Access | Times Cited: 384
Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies
Piyoosh Sharma, Pavan Srivastava, Ankit Seth, et al.
Progress in Neurobiology (2018) Vol. 174, pp. 53-89
Closed Access | Times Cited: 285
Piyoosh Sharma, Pavan Srivastava, Ankit Seth, et al.
Progress in Neurobiology (2018) Vol. 174, pp. 53-89
Closed Access | Times Cited: 285
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Piotr Lewczuk, Peter Riederer, Sid E. O’Bryant, et al.
The World Journal of Biological Psychiatry (2017) Vol. 19, Iss. 4, pp. 244-328
Open Access | Times Cited: 258
Piotr Lewczuk, Peter Riederer, Sid E. O’Bryant, et al.
The World Journal of Biological Psychiatry (2017) Vol. 19, Iss. 4, pp. 244-328
Open Access | Times Cited: 258
Plant alkaloids as drug leads for Alzheimer's disease
Yu Pong Ng, Terry C. T. Or, Nancy Y. Ip
Neurochemistry International (2015) Vol. 89, pp. 260-270
Closed Access | Times Cited: 217
Yu Pong Ng, Terry C. T. Or, Nancy Y. Ip
Neurochemistry International (2015) Vol. 89, pp. 260-270
Closed Access | Times Cited: 217
Air pollution, a rising environmental risk factor for cognition, neuroinflammation and neurodegeneration: The clinical impact on children and beyond
Lilian Calderón‐Garcidueñas, Emmanuelle Leray, Pouria Heydarpour, et al.
Revue Neurologique (2015) Vol. 172, Iss. 1, pp. 69-80
Open Access | Times Cited: 201
Lilian Calderón‐Garcidueñas, Emmanuelle Leray, Pouria Heydarpour, et al.
Revue Neurologique (2015) Vol. 172, Iss. 1, pp. 69-80
Open Access | Times Cited: 201
Alzheimer’s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways
Na Zhao, Yingxue Ren, Yu Yamazaki, et al.
Neuron (2020) Vol. 106, Iss. 5, pp. 727-742.e6
Open Access | Times Cited: 191
Na Zhao, Yingxue Ren, Yu Yamazaki, et al.
Neuron (2020) Vol. 106, Iss. 5, pp. 727-742.e6
Open Access | Times Cited: 191
Endo-lysosomal dysregulations and late-onset Alzheimer’s disease: impact of genetic risk factors
Zoë P. Van Acker, Marine Bretou, Wim Annaert
Molecular Neurodegeneration (2019) Vol. 14, Iss. 1
Open Access | Times Cited: 188
Zoë P. Van Acker, Marine Bretou, Wim Annaert
Molecular Neurodegeneration (2019) Vol. 14, Iss. 1
Open Access | Times Cited: 188
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia
Nagaendran Kandiah, Ming‐Chyi Pai, Vorapun Senanarong, et al.
Clinical Interventions in Aging (2017) Vol. Volume 12, pp. 697-707
Open Access | Times Cited: 178
Nagaendran Kandiah, Ming‐Chyi Pai, Vorapun Senanarong, et al.
Clinical Interventions in Aging (2017) Vol. Volume 12, pp. 697-707
Open Access | Times Cited: 178
Neuronal ROS-induced glial lipid droplet formation is altered by loss of Alzheimer’s disease–associated genes
Matthew J. Moulton, Scott Barish, Isha Ralhan, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 52
Open Access | Times Cited: 119
Matthew J. Moulton, Scott Barish, Isha Ralhan, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 52
Open Access | Times Cited: 119
Brain aging shows nonlinear transitions, suggesting a midlife “critical window” for metabolic intervention
Botond Antal, Helena van Nieuwenhuizen, Anthony G. Chesebro, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 10
Open Access | Times Cited: 2
Botond Antal, Helena van Nieuwenhuizen, Anthony G. Chesebro, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 10
Open Access | Times Cited: 2
Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer’s disease
Jeffrey L. Cummings, Kate Zhong, Jefferson W. Kinney, et al.
Alzheimer s Research & Therapy (2016) Vol. 8, Iss. 1
Open Access | Times Cited: 159
Jeffrey L. Cummings, Kate Zhong, Jefferson W. Kinney, et al.
Alzheimer s Research & Therapy (2016) Vol. 8, Iss. 1
Open Access | Times Cited: 159
Leon M. Tai, Shivesh Ghura, Kevin P. Koster, et al.
Journal of Neurochemistry (2015) Vol. 133, Iss. 4, pp. 465-488
Open Access | Times Cited: 132
Apolipoprotein E as a Therapeutic Target in Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence
Yu Yamazaki, Meghan M. Painter, Guojun Bu, et al.
CNS Drugs (2016) Vol. 30, Iss. 9, pp. 773-789
Open Access | Times Cited: 128
Yu Yamazaki, Meghan M. Painter, Guojun Bu, et al.
CNS Drugs (2016) Vol. 30, Iss. 9, pp. 773-789
Open Access | Times Cited: 128
ApoE4 and Aβ Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation
Abhik Sen, Thomas J. Nelson, Daniel L. Alkon
Journal of Neuroscience (2015) Vol. 35, Iss. 19, pp. 7538-7551
Open Access | Times Cited: 118
Abhik Sen, Thomas J. Nelson, Daniel L. Alkon
Journal of Neuroscience (2015) Vol. 35, Iss. 19, pp. 7538-7551
Open Access | Times Cited: 118
Retinal changes in Alzheimer's disease— integrated prospects of imaging, functional and molecular advances
Veer Bala Gupta, Nitin Chitranshi, Jurre den Haan, et al.
Progress in Retinal and Eye Research (2020) Vol. 82, pp. 100899-100899
Open Access | Times Cited: 116
Veer Bala Gupta, Nitin Chitranshi, Jurre den Haan, et al.
Progress in Retinal and Eye Research (2020) Vol. 82, pp. 100899-100899
Open Access | Times Cited: 116
The pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer's disease
Mounir Belkouch, Mayssa Hachem, Abdeljalil Elgot, et al.
The Journal of Nutritional Biochemistry (2016) Vol. 38, pp. 1-11
Closed Access | Times Cited: 112
Mounir Belkouch, Mayssa Hachem, Abdeljalil Elgot, et al.
The Journal of Nutritional Biochemistry (2016) Vol. 38, pp. 1-11
Closed Access | Times Cited: 112
Healthy Aging and Dementia: Two Roads Diverging in Midlife?
Katherine E. Irwin, Claire E. Sexton, Tarun Daniel, et al.
Frontiers in Aging Neuroscience (2018) Vol. 10
Open Access | Times Cited: 110
Katherine E. Irwin, Claire E. Sexton, Tarun Daniel, et al.
Frontiers in Aging Neuroscience (2018) Vol. 10
Open Access | Times Cited: 110
